-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-01-14
GRI:NSD-GRI Bio Inc. (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.749Change
+0.02 (+2.60)%Market Cap
N/AVolume
0.18MAnalyst Target
N/AN/A
Verdict
Values as of: 2025-01-14
COMMON STOCK | Biotechnology |
Last Closing
USD 0.749Change
+0.02 (+2.60)%Market Cap
N/AVolume
0.18MAnalyst Target
N/AN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
-1.71 (-0.41%) |
USD 104.84B |
REGN | Regeneron Pharmaceuticals Inc |
-26.03 (-3.63%) |
USD 78.92B |
ARGX | argenx NV ADR |
-4.80 (-0.72%) |
USD 39.62B |
ALNY | Alnylam Pharmaceuticals Inc |
-17.76 (-6.88%) |
USD 30.22B |
MRNA | Moderna Inc |
-0.69 (-1.96%) |
USD 18.29B |
UTHR | United Therapeutics Corporatio.. |
+1.82 (+0.50%) |
USD 15.91B |
RPRX | Royalty Pharma Plc |
+0.04 (+0.13%) |
USD 15.05B |
SMMT | Summit Therapeutics PLC |
-1.53 (-8.39%) |
USD 13.43B |
INCY | Incyte Corporation |
-0.44 (-0.61%) |
USD 13.41B |
BMRN | Biomarin Pharmaceutical Inc |
-3.18 (-4.75%) |
USD 12.74B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
UKPH:XETRA | iShares UK Property UCITS.. | 3.23 % | 0.00 % |
+0.02 (+0.61%) |
N/A |
IUKP:SW | iShares UK Property UCITS.. | 3.18 % | 0.00 % |
+0.01 (+0.61%) |
USD 0.57B |
IUKP:LSE | iShares UK Property UCITS | 0.00 % | 0.00 % |
+2.00 (+0.61%) |
USD 0.57B |
UKRE:LSE | iShares MSCI Target UK Re.. | 0.00 % | 0.00 % |
+0.65 (+0.61%) |
USD 0.12B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -9.58% | 35% | F | 17% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -9.58% | 35% | F | 17% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -97.17% | 3% | F | 1% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -97.17% | 3% | F | 1% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -100.00% | N/A | F | N/A | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -100.00% | N/A | F | N/A | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -35.93% | 8% | B- | 4% | F | ||
Dividend Return | -35.93% | 8% | B- | 4% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 46.84% | 66% | D+ | 41% | F | ||
Risk Adjusted Return | -76.71% | 13% | F | 8% | B- | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This stock has shown below median earnings growth in the previous 5 years compared to its sector